

Mongoose Bio, Inc. Awarded \$10.6 Million from the Cancer Prevention and Research Institute of Texas (CPRIT)

CPRIT funds would support clinical trials of lead candidate MGB-001 in a number of oncology indications.

HOUSTON—November 16, 2023—Mongoose Bio, Inc., a private clinical-stage biopharmaceutical company pioneering next-generation precision T-cell based therapies targeting solid cancers today announced that the Company received notice of a Product Development New Technologies Company Award of \$10.6 Million from the Cancer Prevention and Research Institute of Texas (CPRIT) to support clinical studies of its lead product candidate, MGB-001.

The CPRIT award would support a portion of the Company’s three-year global clinical program for the treatment of patients suffering from refractory gastric, esophageal, or non-small cell lung cancer (NSCLC). The planned study is designed to evaluate the benefit of MGB-001, an epigenetically reprogrammed autologous TCR-T cell therapy directed against a target that is both highly immunogenic and broadly expressed in many solid tumors. This therapy is built upon 17 years of pioneering work by founder Dr. Cassian Yee at his lab at the University of Texas MD Anderson Cancer Center (MDACC). Dr. Yee is a CPRIT Scholar.

“We are delighted that CPRIT and the Oversight Committee have approved this award to help us accelerate the clinical development of MGB-001 in various cancers,” said Peter Hoang, Interim CEO of Mongoose Bio. “We are very grateful for this support from the State of Texas, which will enable us to accelerate our clinical programs for patients who have failed approved, front-line therapies in these difficult tumor indications. Many of our patients have few remaining treatment options, and we believe our proprietary epigenetic central memory T cell reprogramming has the potential to drive not only an enhanced response to T cell therapy, but also superior durability of those responses with a more persistent population of true central memory T cells. This technology has previously demonstrated very promising early clinical responses when used to enhance non-genetically modified T cells. The New Technologies Award from CPRIT will allow us to more fully evaluate MGB-001 in clinical trials.”

About CPRIT

The Cancer Prevention and Research Institute of Texas (CPRIT) was created by the Texas Legislature and approved in 2007 by a statewide vote. CPRIT funds cancer research in Texas in the areas of cancer research, product development, and prevention through bonds issued by the state of Texas. The total amount awarded thus far is \$3.38 Billion in grants to Texas researchers, institutions, and organizations. In the interests of advancing scientific and clinical knowledge, programs made possible with CPRIT funding have brought 302 distinguished researchers to Texas as well as supported the establishment, expansion or relocation of 62 companies to Texas. CPRIT has also provided more than \$9.04 Million in life-saving education, training, prevention and early detection services to Texans.

About Mongoose Bio, Inc.

Mongoose Bio is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for solid cancers. Mongoose Bio is using a combination of proprietary methodologies including a Immunopeptidome Discovery Platform (IDP) and Epigenetic T Cell Reprogramming (ECMR) to develop next-generation adoptive TCR-T cell therapies. More information can be found at www.mongoosebio.com.

Source: Mongoose Bio, Inc.

Investors & Media:

Peter Hoang
Interim CEO
(917) 916-6644
peterhoang@mongoosebio.com

N Michael Greenberg, PhD
Chief Strategy Officer
(858) 947-8535
nmg@mongoosebio.com